Skip to main content

Articles

Page 28 of 60

  1. The aim was to assess coronary atherosclerosis, plaque morphology and associations to cardiovascular risk factors and epicardial adipose tissue (EAT) in patients with long duration of type 1 diabetes mellitus ...

    Authors: Mona Svanteson, Kristine Bech Holte, Ylva Haig, Nils Einar Kløw and Tore Julsrud Berg
    Citation: Cardiovascular Diabetology 2019 18:58
    Content type: Original investigation Published on:

  2. Myocardial energetic efficiency (MEE), is a strong predictor of CV events in hypertensive patient and is reduced in patients with diabetes and metabolic syndrome. We hypothesized that severity of insulin resis...

    Authors: Costantino Mancusi, Giovanni de Simone, Lyle G. Best, Wenyu Wang, Ying Zhang, Mary J. Roman, Elisa T. Lee, Barbara V. Howard and Richard B. Devereux
    Citation: Cardiovascular Diabetology 2019 18:56
    Content type: Original investigation Published on:

  3. Liraglutide is an antidiabetic agent with cardioprotective effect. The purpose of this study is to test efficacy of liraglutide to improve diabetic cardiomyopathy in patients with diabetes mellitus type 2 (DM2...

    Authors: Maurice B. Bizino, Ingrid M. Jazet, Jos J. M. Westenberg, Huub J. van Eyk, Elisabeth H. M. Paiman, Jan W. A. Smit and Hildebrandus J. Lamb
    Citation: Cardiovascular Diabetology 2019 18:55
    Content type: Original investigation Published on:

    The Correction to this article has been published in Cardiovascular Diabetology 2019 18:101

  4. With an increasing global burden of coronary artery disease (CAD), early detection and timely management of risk factors are crucial to reduce morbidity and mortality in such patients. Diabetes mellitus (DM) i...

    Authors: Fei Luo, Avash Das, Jingfei Chen, Panyun Wu, Xiangping Li and Zhenfei Fang
    Citation: Cardiovascular Diabetology 2019 18:54
    Content type: Review Published on:

  5. Prediabetes is a well-established risk factor for progression to overt diabetes mellitus (DM), which is in turn associated with development of hypertension (HTN) and vice versa. However, the role of prediabete...

    Authors: Mika Geva, Gadi Shlomai, Anat Berkovich, Elad Maor, Avshalom Leibowitz, Alexander Tenenbaum and Ehud Grossman
    Citation: Cardiovascular Diabetology 2019 18:53
    Content type: Original investigation Published on:

  6. Despite revascularisation, a large proportion of acute coronary syndrome (ACS) patients continue to experience major adverse cardiovascular events (MACEs), which are worsened by diabetes mellitus (DM). Fibrino...

    Authors: Lisha Zhang, Chenbo Xu, Junhui Liu, Xiaofang Bai, Ruifeng Li, Lijun Wang, Juan Zhou, Yue Wu and Zuyi Yuan
    Citation: Cardiovascular Diabetology 2019 18:52
    Content type: Original investigation Published on:

  7. Evidence from imaging studies suggests a high prevalence of coronary artery disease (CAD) in patients with type 2 diabetes mellitus (T2DM). However, there are no criteria for initiating screening for CAD in th...

    Authors: Shreenidhi M. Venuraju, Avijit Lahiri, Anand Jeevarethinam, Mark Cohen, Daniel Darko, Devaki Nair, Miranda Rosenthal and Roby D. Rakhit
    Citation: Cardiovascular Diabetology 2019 18:51
    Content type: Original investigation Published on:

  8. To investigate the effect of visit-to-visit fasting plasma glucose (FPG) variability on the left cardiac structure and function in patients with type 2 diabetes mellitus (T2DM).

    Authors: Xixiang Tang, Junlin Zhong, Hui Zhang, Yanting Luo, Xing Liu, Long Peng, Yanling Zhang, Xiaoxian Qian, Boxiong Jiang, Jinlai Liu, Suhua Li and Yanming Chen
    Citation: Cardiovascular Diabetology 2019 18:50
    Content type: Original investigation Published on:

  9. Type 2 diabetes mellitus (T2DM) is associated with a hypercoagulable state and increased neutrophil extracellular traps formation (NETosis). We investigated predictors of NETosis and cell death markers in circ...

    Authors: Agata H. Bryk, Shannon M. Prior, Krzysztof Plens, Malgorzata Konieczynska, Jerzy Hohendorff, Maciej T. Malecki, Saulius Butenas and Anetta Undas
    Citation: Cardiovascular Diabetology 2019 18:49
    Content type: Original investigation Published on:

  10. The importance of triglycerides (TG) level as a risk factor for cardiovascular diseases (CVD) has been extensively investigated in the general population; however, their relationship in patients with type 2 di...

    Authors: Xiaofeng Ye, Wen Kong, Mohammad Ishraq Zafar and Lu-Lu Chen
    Citation: Cardiovascular Diabetology 2019 18:48
    Content type: Review Published on:

  11. The cardiovascular (CV) safety in terms of heart failure among different classes of treatment remains largely unknown. We sought to assess the comparative effect of these agents on heart failure outcomes.

    Authors: Da-ya Yang, Xin He, Hui-wei Liang, Shao-zhao Zhang, Xiang-bin Zhong, Chu-fan Luo, Zhi-min Du, Jian-gui He, Xiao-dong Zhuang and Xin-xue Liao
    Citation: Cardiovascular Diabetology 2019 18:47
    Content type: Review Published on:

  12. SGLT2-inhibitors are potent antihyperglycemic drugs for patients with type 2 diabetes and have been shown to reduce body weight. However, it is unclear which body compartments are reduced and to what extent.

    Authors: Anja Schork, Janine Saynisch, Andreas Vosseler, Benjamin Assad Jaghutriz, Nils Heyne, Andreas Peter, Hans-Ulrich Häring, Norbert Stefan, Andreas Fritsche and Ferruh Artunc
    Citation: Cardiovascular Diabetology 2019 18:46
    Content type: Original investigation Published on:

  13. Sodium glucose co-transporter 2 inhibitor (SGLT2i), a new class of anti-diabetic drugs acting on inhibiting glucose resorption by kidneys, is shown beneficial in reduction of heart failure hospitalization and ...

    Authors: Hsiang-Chun Lee, Yi-Lin Shiou, Shih-Jie Jhuo, Chia-Yuan Chang, Po-Len Liu, Wun-Jyun Jhuang, Zen-Kong Dai, Wei-Yu Chen, Yun-Fang Chen and An-Sheng Lee
    Citation: Cardiovascular Diabetology 2019 18:45
    Content type: Original investigation Published on:

  14. Empagliflozin has been shown to reduce cardiovascular mortality, but the underlying pathogenetic mechanisms are poorly understood. It was previously demonstrated that empagliflozin improved arterial stiffness.

    Authors: Agnes Bosch, Christian Ott, Susanne Jung, Kristina Striepe, Marina V. Karg, Dennis Kannenkeril, Thomas Dienemann and Roland E. Schmieder
    Citation: Cardiovascular Diabetology 2019 18:44
    Content type: Original investigation Published on:

  15. Patients with type 1 diabetes (T1DM) typically have normal or even elevated plasma high density lipoprotein (HDL) cholesterol concentrations; however, HDL protein composition can be altered without a change in...

    Authors: Evgenia Gourgari, Junfeng Ma, Martin P. Playford, Nehal N. Mehta, Radoslav Goldman, Alan T. Remaley and Scott M. Gordon
    Citation: Cardiovascular Diabetology 2019 18:43
    Content type: Original investigation Published on:

  17. We aimed to compare early and late outcomes after carotid endarterectomy (CEA) between Korean type 2 diabetic and non-diabetic patients and to investigate the impact of diabetes on the overall incidence of car...

    Authors: Min-Jae Jeong, Hyunwook Kwon, Chang Hee Jung, Sun U. Kwon, Min-Ju Kim, Youngjin Han, Tae-Won Kwon and Yong-Pil Cho
    Citation: Cardiovascular Diabetology 2019 18:41
    Content type: Original investigation Published on:

  18. Diabetic nephropathy (DN) is characterized by glomerular and tubulointerstitial injury, proteinuria and remodeling. Here we examined whether the combination of an inhibitor of neprilysin (sacubitril), a natriu...

    Authors: Javad Habibi, Annayya R. Aroor, Nitin A. Das, Camila M. Manrique-Acevedo, Megan S. Johnson, Melvin R. Hayden, Ravi Nistala, Charles Wiedmeyer, Bysani Chandrasekar and Vincent G. DeMarco
    Citation: Cardiovascular Diabetology 2019 18:40
    Content type: Original investigation Published on:

  19. The efficacy of cell transplantation in heart failure is reportedly modest, but adjuvant drugs combined with cell therapy may improve this efficacy. Peroxisome proliferator-activated receptor (PPAR)γ, one of t...

    Authors: Daisuke Mori, Shigeru Miyagawa, Ryohei Matsuura, Nagako Sougawa, Satsuki Fukushima, Takayoshi Ueno, Koichi Toda, Toru Kuratani, Koichi Tomita, Norikazu Maeda, Iichiro Shimomura and Yoshiki Sawa
    Citation: Cardiovascular Diabetology 2019 18:39
    Content type: Original investigation Published on:

  20. Using a meta-analysis of randomized controlled trials (RCTs), this study aimed to investigate the efficacy and safety of pemafibrate, a novel selective peroxisome proliferator-activated receptor α modulator, i...

    Authors: Satoshi Ida, Ryutaro Kaneko and Kazuya Murata
    Citation: Cardiovascular Diabetology 2019 18:38
    Content type: Original investigation Published on:

  21. Subtle impairments in left ventricular (LV) function and geometry are common findings in individuals with diabetes. However, whether these impairments precede the development of diabetes mellitus (DM) is not e...

    Authors: Daniel Modin, Rasmus Møgelvang, Peter Godsk Jørgensen, Magnus Thorsten Jensen, Jelena P. Seferovic and Tor Biering-Sørensen
    Citation: Cardiovascular Diabetology 2019 18:37
    Content type: Original investigation Published on:

  22. Because weight control is a cornerstone of diabetes management, it is important to understand the relationship of weight change to risk of cardiovascular disease (CVD) among patients with type 2 diabetes melli...

    Authors: Mee Kyoung Kim, Kyungdo Han, Eun Sil Koh, Eun Sook Kim, Min-Kyung Lee, Ga Eun Nam and Hyuk-Sang Kwon
    Citation: Cardiovascular Diabetology 2019 18:36
    Content type: Original investigation Published on:

  23. This pathophysiological study addressed the hypothesis that soluble epoxide hydrolase (sEH), which metabolizes the vasodilator and anti-inflammatory epoxyeicosatrienoic acids (EETs) to dihydroxyeicosatrienoic ...

    Authors: Thomas Duflot, Lucile Moreau-Grangé, Clothilde Roche, Michèle Iacob, Julien Wils, Isabelle Rémy-Jouet, Anne-Françoise Cailleux, Matthieu Leuillier, Sylvanie Renet, Dongyang Li, Christophe Morisseau, Fabien Lamoureux, Vincent Richard, Gaëtan Prévost, Robinson Joannidès and Jérémy Bellien
    Citation: Cardiovascular Diabetology 2019 18:35
    Content type: Original investigation Published on:

  24. Exercise, when performed on a regular basis, is a well-accepted strategy to improve vascular function in patients with type 2 diabetes. However, the exercise intensity that yields maximal adaptations on struct...

    Authors: João P. Magalhães, Xavier Melo, Inês R. Correia, Rogério T. Ribeiro, João Raposo, Hélder Dores, Manuel Bicho and Luís B. Sardinha
    Citation: Cardiovascular Diabetology 2019 18:34
    Content type: Original investigation Published on:

  25. To evaluate the characteristics of type 2 diabetes (T2DM) patients with or without chronic kidney disease (CKD) in Germany.

    Authors: Peter Bramlage, Stefanie Lanzinger, Gesine van Mark, Eva Hess, Simon Fahrner, Christoph H. J. Heyer, Mathias Friebe, Jochen Seufert, Thomas Danne and Reinhard W. Holl
    Citation: Cardiovascular Diabetology 2019 18:33
    Content type: Original investigation Published on:

  26. The authors have retracted this article [1] because they have identified serious errors in their data analysis which change the conclusions of their study. All authors agree with this retraction.

    Authors: Kyoung Min Kim, Kyong Yeun Jung, Han Mi Yun, Seo Young Lee, Tae Jung Oh, Hak Chul Jang and Soo Lim
    Citation: Cardiovascular Diabetology 2019 18:32
    Content type: Retraction Note Published on:

    The original article was published in Cardiovascular Diabetology 2017 16:146

  27. Diabetes mellitus (DM) adversely affects morbidity and mortality for major atherosclerosis-related cardiovascular diseases and is associated with increased risk for the development of aortic stenosis. Clinical...

    Authors: Eilon Ram, Alexander Kogan, Shany Levin, Enrique Z. Fisman, Alexander Tenenbaum, Ehud Raanani and Leonid Sternik
    Citation: Cardiovascular Diabetology 2019 18:31
    Content type: Original investigation Published on:

  28. The 4th Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes & Cardiovascular Disease (D&CVD) EASD Study Group was held in Munich on 25–26 October 2018. As in previous years, this summit served as a refe...

    Authors: Oliver Schnell, Eberhard Standl, Doina Catrinoiu, Baruch Itzhak, Nebojsa Lalic, Dario Rahelic, Jan Skrha, Paul Valensi and Antonio Ceriello
    Citation: Cardiovascular Diabetology 2019 18:30
    Content type: Commentary Published on:

  29. Cardiovascular autonomic neuropathy (CAN) is a major cause of morbidity and mortality in diabetes patients. Although several risk factors for CAN progression have been established, whether CAN is reversible re...

    Authors: Ji Eun Jun, Seung-Eun Lee, Min Sun Choi, Sung Woon Park, You-Cheol Hwang and Jae Hyeon Kim
    Citation: Cardiovascular Diabetology 2019 18:29
    Content type: Original investigation Published on:

  30. To determine the impact of dipeptidyl peptidase-4 inhibitor (DPP4i) on the risk of major cardiocerebrovascular and renal outcomes compared with sulfonylurea (SU) combined with metformin in patients with type 2...

    Authors: Kyoung Jin Kim, Jimi Choi, Juneyoung Lee, Jae Hyun Bae, Jee Hyun An, Hee Young Kim, Hye Jin Yoo, Ji A. Seo, Nan Hee Kim, Kyung Mook Choi, Sei Hyun Baik, Sin Gon Kim and Nam Hoon Kim
    Citation: Cardiovascular Diabetology 2019 18:28
    Content type: Original investigation Published on:

  31. Glycemic variability is associated with worse outcomes after cardiac surgery, but the prognosis value of early glycemic variability after transcatheter aortic valve implantation is not known. This study was th...

    Authors: Guillaume Besch, Sebastien Pili-Floury, Caroline Morel, Martine Gilard, Guillaume Flicoteaux, Lucie Salomon du Mont, Andrea Perrotti, Nicolas Meneveau, Sidney Chocron, Francois Schiele, Herve Le Breton, Emmanuel Samain and Romain Chopard
    Citation: Cardiovascular Diabetology 2019 18:27
    Content type: Original investigation Published on:

  32. The prevalence of asymptomatic coronary artery disease (CAD) in type 2 diabetes (T2D) is unclear. We investigated the extent and prevalence of asymptomatic CAD in T2D patients by utilizing invasive coronary an...

    Authors: Satish Arora, Anne Pernille Ofstad, Geir R. Ulimoen, KÃ¥re I. Birkeland, Knut Endresen, Lars Gullestad and Odd Erik Johansen
    Citation: Cardiovascular Diabetology 2019 18:26
    Content type: Original investigation Published on:

  33. Percutaneous coronary intervention (PCI) in patients with diabetes mellitus (DM) remains challenging even with modern drug-eluting stents (DES) due to high rates of repeat revascularization. Everolimus-eluting...

    Authors: T. M. Hommels, R. S. Hermanides, S. Rasoul, B. Berta, A. J. J. IJsselmuiden, G. A. J. Jessurun, E. Benit, B. Pereira, G. De Luca and E. Kedhi
    Citation: Cardiovascular Diabetology 2019 18:25
    Content type: Original investigation Published on:

  34. In patients with Normal Glucose Tolerance (NGT) some causes of ischemic heart disease (IHD) were not completely investigated. The role both of metabolic milieu and adipokines in IHD progression was not fully inve...

    Authors: Ferdinando Carlo Sasso, Pia Clara Pafundi, Raffaele Marfella, Paolo Calabrò, Federico Piscione, Fulvio Furbatto, Giovanni Esposito, Raffaele Galiero, Felice Gragnano, Luca Rinaldi, Teresa Salvatore, Michele D’Amico, Luigi Elio Adinolfi and Celestino Sardu
    Citation: Cardiovascular Diabetology 2019 18:24
    Content type: Original investigation Published on:

  35. Following publication of the original article [1], based on the authors review, the GLP1 receptor agonists in type 2 diabetes published in Cardiovascular Diabetology, a meta-analysis of GLP-1 and non-GLP-1 bas...

    Authors: Andrei C. Sposito, Otávio Berwanger, Luiz Sérgio F. de Carvalho and José Francisco Kerr Saraiva
    Citation: Cardiovascular Diabetology 2019 18:23
    Content type: Correction Published on:

    The original article was published in Cardiovascular Diabetology 2018 17:157

  36. Patients with type 2 diabetes mellitus are at an increased risk of adverse cardiovascular events compared to those without diabetes. The timing, relative to disease onset, and degree of glycemic control that r...

    Authors: Jaskanwal D. Sara, Riad Taher, Nikhil Kolluri, Adrian Vella, Lilach O. Lerman and Amir Lerman
    Citation: Cardiovascular Diabetology 2019 18:22
    Content type: Original investigation Published on:

  37. There is a mutual interaction between inflammation and endocrine disorders in the development of coronary artery disease (CAD). Growth differentiation factor-15 (GDF-15) is associated with CAD, and the effects...

    Authors: Huan Liu, Yongnan Lyu, Di Li, Yan Cui, Yun Huang, Wen Dai and Yan Li
    Citation: Cardiovascular Diabetology 2019 18:21
    Content type: Original investigation Published on:

  38. Sotagliflozin is a dual sodium–glucose co-transporter-2 and 1 (SGLT2/1) inhibitor for the treatment of both type 1 (T1D) and type 2 diabetes (T2D). Sotagliflozin inhibits renal sodium–glucose co-transporter 2 ...

    Authors: Chiara Maria Assunta Cefalo, Francesca Cinti, Simona Moffa, Flavia Impronta, Gian Pio Sorice, Teresa Mezza, Alfredo Pontecorvi and Andrea Giaccari
    Citation: Cardiovascular Diabetology 2019 18:20
    Content type: Review Published on:

  40. Impaired glucose tolerance (IGT) is a risk factor for the development of diabetes and related complications that ensue. Early identification of at-risk individuals might be beneficial to reduce or delay the pr...

    Authors: Lucia La Sala, Simona Mrakic-Sposta, Elena Tagliabue, Francesco Prattichizzo, Stefano Micheloni, Elena Sangalli, Claudia Specchia, Anna Chiara Uccellatore, Silvia Lupini, Gaia Spinetti, Paola de Candia and Antonio Ceriello
    Citation: Cardiovascular Diabetology 2019 18:18
    Content type: Original investigation Published on:

  41. Soluble Receptor for Advanced Glycation End Products (sRAGE) may be considered a marker inversely related to inflammation and its participation has been established in patients with advanced atherosclerotic va...

    Authors: Andrea Maria Maresca, Luigina Guasti, Sara Bozzini, Christian Mongiardi, Nicolò Tandurella, Rossana Corso, Francesco G. Zerba, Alessandro Squizzato, Leonardo Campiotti, Francesco Dentali, Catherine Klersy, Anna M. Grandi and Colomba Falcone
    Citation: Cardiovascular Diabetology 2019 18:17
    Content type: Original investigation Published on:

  42. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) is the first class of anti-diabetes treatment that reduces mortality and risk for hospitalization due to heart failure. In clinical studies it has been shown ...

    Authors: Damilola D. Adingupu, Sven O. Göpel, Julia Grönros, Margareta Behrendt, Matus Sotak, Tasso Miliotis, Ulrika Dahlqvist, Li-Ming Gan and Ann-Cathrine Jönsson-Rylander
    Citation: Cardiovascular Diabetology 2019 18:16
    Content type: Original investigation Published on:

  43. Hyperglycaemia associated with myocardial oxidative stress and fibrosis is the main cause of diabetic cardiomyopathy. Empagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor has recently been reporte...

    Authors: Chenguang Li, Jie Zhang, Mei Xue, Xiaoyu Li, Fei Han, Xiangyang Liu, Linxin Xu, Yunhong Lu, Ying Cheng, Ting Li, Xiaochen Yu, Bei Sun and Liming Chen
    Citation: Cardiovascular Diabetology 2019 18:15
    Content type: Original investigation Published on:

  44. Carotid artery intima-media thickness (cIMT) progression is a surrogate marker of atherosclerosis with a high predictive value for future CVD risk. This study evaluates the comparative efficacies of lipid lowe...

    Authors: Rongzhong Huang, Kerry Mills, Julio Romero, Yan Li, Zicheng Hu, Yu Cao, Hua Huang, Yu Xu and Lihong Jiang
    Citation: Cardiovascular Diabetology 2019 18:14
    Content type: Original investigation Published on:

  45. The diabetic heart undergoes remodelling contributing to an increased incidence of heart failure in individuals with diabetes at a later stage. The molecular regulators that drive this process in the diabetic ...

    Authors: Shruti Rawal, Prashanth Thevakar Nagesh, Sean Coffey, Isabelle Van Hout, Ivor F. Galvin, Richard W. Bunton, Philip Davis, Michael J. A. Williams and Rajesh Katare
    Citation: Cardiovascular Diabetology 2019 18:13
    Content type: Original investigation Published on:

  47. Increasing evidence has suggested that the presence of remnant lipoproteins is a significant risk factor for atherosclerosis. Remnant lipoproteins are lipoproteins that are rich in triglycerides (TGs), and the...

    Authors: Zheng Qin, Kuo Zhou, Yue-ping Li, Jian-long Wang, Wan-jun Cheng, Cheng-ping Hu, Chao Shi, Hua He and Yu-jie Zhou
    Citation: Cardiovascular Diabetology 2019 18:11
    Content type: Original investigation Published on:

  48. Novel studies have increased our knowledge regarding optimal treatment options in diabetes. Key studies that have broadened our knowledge about optimal treatment options in diabetes in recent years are cardiov...

    Authors: Katharina Fritzen and Oliver Schnell
    Citation: Cardiovascular Diabetology 2019 18:10
    Content type: Commentary Published on:

  49. Reports on body mass index (BMI) trajectories from childhood into late adolescence, their determinants, and subsequent cardiometabolic risk markers, particularly among European populations have been few. Moreo...

    Authors: Kolade Oluwagbemigun, Anette E. Buyken, Ute Alexy, Matthias Schmid, Christian Herder and Ute Nöthlings
    Citation: Cardiovascular Diabetology 2019 18:9
    Content type: Original investigation Published on:

  50. Sortilin is a 95-kDa protein which has recently been linked to circulating cholesterol concentration and lifetime risk of developing significant atherosclerotic disease. Sortilin is found inside different cell...

    Authors: Federico Biscetti, Nicola Bonadia, Francesco Santini, Flavia Angelini, Elisabetta Nardella, Dario Pitocco, Angelo Santoliquido, Marco Filipponi, Raffaele Landolfi and Andrea Flex
    Citation: Cardiovascular Diabetology 2019 18:5
    Content type: Original investigation Published on:
journal logo

Cardiovascular Diabetology is affiliated with Sackler Faculty of Medicine, Tel-Aviv University

New Content Item

Submit manuscript

Annual Journal Metrics

  • 2022 Citation Impact
    9.3 - 2-year Impact Factor
    9.6 - 5-year Impact Factor
    2.054 - SNIP (Source Normalized Impact per Paper)
    2.361 - SJR (SCImago Journal Rank)

    2023 Speed
    4 days submission to first editorial decision for all manuscripts (Median)
    56 days submission to accept (Median)

    2023 Usage 
    2,523,778 downloads
    3,115 Altmetric mentions 

Cardiovascular Diabetology

ISSN: 1475-2840